Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.53 |
| ▸ | GMPS | P49915 | 1/20 | 0.50 |
| ▸ | SLC28A1 | O00337 | 2/20 | 0.47 |
| ▸ | PI4KA | P42356 | 2/20 | 0.47 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.47 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.47 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.47 |
| ▸ | GAPDH | P04406 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | STAT6 | P42226 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30676636 | 1.00 | ADORA3 (0.53) | ADORA3ADORA2AGMPSSLC28A1PI4KA | |
| SCHEMBL29508945 | 0.88 | ADORA3 (0.53) | ADORA3ADORA2AGMPSSLC28A1PI4KA | |
| SCHEMBL4944757 | 0.88 | ADORA3 (0.53) | ADORA3ADORA2AGMPSSLC28A1PI4KA | |
| SCHEMBL8003530 | 0.88 | ADORA3 (0.53) | ADORA3ADORA2AGMPSSLC28A1PI4KA | |
| SCHEMBL35210134 | 0.88 | ADORA3 (0.53) | ADORA3ADORA2AGMPSSLC28A1PI4KA | |
| SCHEMBL5181220 | 0.88 | ADORA3 (0.53) | ADORA3ADORA2AGMPSSLC28A1PI4KA | |
| SCHEMBL2270714 | 0.87 | ADORA3 (0.54) | ADORA3ADORA2AGMPSSLC28A1PI4KA | |
| SCHEMBL29639535 | 0.87 | ADORA3 (0.54) | ADORA3ADORA2AGMPSSLC28A1PI4KA | |
| Psicofuranine SCHEMBL29441281 | 0.87 | GMPS (0.61) | ADORA3ADORA2AGMPSSLC28A1PI4KA | |
| Psicofuranine SCHEMBL691065 | 0.87 | GMPS (0.61) | ADORA3ADORA2AGMPSSLC28A1PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133880-B2 | Purine derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2012-03-13 | — | — | US | disclosed |
| EP-1802316-B1 | PURINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORP (US) | 2011-11-02 | — | — | EP | disclosed |
| US-20110059915-A1 | PURINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2011-03-10 | — | — | US | disclosed |
| US-7863253-B2 | Purine Derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| CN-101437526-A | Purine derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORP (US) | 2009-05-20 | — | — | CN | disclosed |
| CN-101404883-A | Purine compounds and methods of use thereof | INOTEK PHARMACEUTICALS CORP (US) | 2009-04-08 | — | — | CN | disclosed |
| EP-1996020-A2 | PURINE COMPOUNDS AND METHODS OF USE THEREOF | Inotek Pharmaceuticals Corporation (US) | 2008-12-03 | — | — | EP | disclosed |
| US-20070238694-A1 | Purine compounds and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-10-11 | — | — | US | disclosed |
| WO-2007111954-A2 | PURINE COMPOUNDS AND METHODS OF USE THEREOF | INOTEK PHAMACEUTICALS CORPORATION (US) | 2007-10-04 | — | — | WO | disclosed |
| EP-1802316-A2 | PURINE DERIVATIVES AND METHODS OF USE THEREOF | Inotek Pharmaceuticals Corporation (US) | 2007-07-04 | — | — | EP | disclosed |
| US-20060128652-A1 | Purine derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2006-06-15 | — | — | US | disclosed |
| WO-2006034190-A2 | PURINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2006-03-30 | — | — | WO | disclosed |
| EP-0061001-A1 | Antiallergic agent comprising derivatives of adenosine | Yamasa Shoyu Kabushiki Kaisha (JP) | 1982-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238694-A1 | Purine compounds and methods of use thereof | PNP, ADORA2A, P2RY1 | ADORA3 28/4885ADORA2A 2/4885GMPS 193/4885 |
| US-20110059915-A1 | PURINE DERIVATIVES AND METHODS OF USE THEREOF | PNP, NUDT1, HPRT1 | ADORA3 26/4885ADORA2A 4/4885GMPS 127/4885 |
| US-20060128652-A1 | Purine derivatives and methods of use thereof | PNP, NUDT1, HPRT1 | ADORA3 26/4885ADORA2A 4/4885GMPS 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.